Skip to main content
. 2013 Jun 19;8(6):e66780. doi: 10.1371/journal.pone.0066780

Table 1. Characteristics of participants according to CVD risk factors.* .

CVD risk factors Total
None Single Cluster
Number 12 026 14 365 20 292 46 683
Prevalence (%) 31.1(30.2–31.9) 32.7(31.9–33.6) 36.2(35.4–37.1)
Age(years)
18–44 77.0(75.7–78.2) 60.6(59.1–62.0) 42.0(40.6–43.5) 59.0(58.1–59.8)
45–64 18.3(17.2–19.4) 30.0(28.7–31.3) 41.5(40.2–42.9) 30.5(29.8–31.3)
≥65 4.7(4.1–5.3) 9.4(8.7–10.2) 16.4(15.5–17.3) 10.5(10.0–10.9)
Male (%) 47.7(46.0–49.5) 50.7(49.1–52.3) 52.9(51.5–54.3) 50.6(49.6–51.5)
High school education or above (%) 37.8(36.1–39.5) 31.2(29.8–32.7) 25.8(24.6–27.0) 31.3(30.5–32.2)
Have health insurance (%) 90.9(89.9–91.9) 91.7(90.9–92.5) 93.5(92.8–94.1) 92.1(91.6–92.6)
Household income (1000 RMB per year) * 24(9–48) 24(9–48) 24(9–48) 24(9–48)
Family history of premature diseases (%) 15.2(13.8–16.7) 18.9(17.5–20.3) 25.4(24.0–26.7) 20.1(19.3–20.9)
Lifestyle risk factors
Habitual drinking (%) 3.1(2.6–3.7) 5.6(5.0–6.3) 8.1(7.3–8.8) 5.7(5.3–6.1)
Leisure-time physical inactivity (%) 82.6(81.3–84.0) 81.7(80.4–82.9) 84.2(83.2–85.2) 82.9(82.2–83.6)
Chronic use of NSAIDs (%) 1.9(1.4–2.5) 4.3(3.6–5.0) 5.0(4.4–5.6) 3.8(3.4–4.2)
Modified DASH score in tertile1 (%) 29.0(27.3–30.7) 33.8(32.2–35.4) 35.3(33.9–36.8) 32.8(31.9–33.8)
Lifestyle score
0 14.1(12.9–15.3) 14.4(13.2–15.5) 11.5(10.7–12.3) 13.2(12.6–13.9)
1 58.1(56.2–60.0) 51.6(49.9–53.3) 51.1(49.5–52.6) 53.5(52.5–54.5)
≥2 27.8(26.1–29.6) 34.0(32.3–35.7) 37.4(35.9–38.9) 33.3(32.4–34.2)

CVD = cardiovascular disease; RMB = Ren Min Bi; NSAIDS = non-steroidal anti-inflammatory drugs; DASH = dietary approaches to stop hypertension.

The categorical variables are presented as prevalence rate (95% confidence intervals), and all prevalence rates are adjusted for synthesized weights.

*

Household income is presented as the median (inter-quartile range) because of substantial skewness.

First-degree relatives suffered from hypertension, diabetes, stroke and/or coronary heart disease, and the onset was before the age of 55 for men or before the age of 65 for women.